HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Q3 revenue up 39% y/y to $493M, royalties up 44% to $341M; FY26 revenue guidance raised to $1.860-1.925B, EPS $8.75-9.05.
What this release says
Halozyme reported third quarter 2026 revenue up 39% year over year to $493 million, with royalty revenue up 44% to $341 million, driven mainly by ENHANZE partner products. The company raised its full year 2026 guidance, now expecting total revenue of $1.860 to $1.925 billion. For a shareholder, the stronger outlook and expanded partner agreements point to continued growth, though new Hypercon and Aerocon investments will weigh on adjusted EBITDA this year.
Key figures
- Q3 total revenue
- $493.0 million
- Q3 royalty revenue
- $341.0 million
- Q3 net income
- $247.0 million
- 2026 total revenue guidance
- $1.860 to $1.925 billion
- 2026 adjusted EBITDA guidance
- $1.240 to $1.290 billion
- 2026 non-GAAP diluted EPS guidance
- $8.75 to $9.05
Positive for shareholders
- Total revenue and royalty revenue both grew at record levels in the quarter.
- Full year 2026 guidance was raised across revenue, adjusted EBITDA and non-GAAP EPS.
- Expanded ENHANZE agreements with argenx, Incyte and Johnson & Johnson add new targets to evaluate.
- A Dutch court found Merck infringes an MDASE patent and granted an injunction against a Keytruda Qlex launch in several European markets.
Negative for shareholders
- Guidance includes new Hypercon and Aerocon investments of approximately $60 million, which reduce adjusted EBITDA and EPS.
- The company completed $400 million in share repurchases this year, and the new $1.5 billion convertible notes add to its debt load.
- Ongoing growth depends on sales of partner products such as VYVGART Hytrulo, DARZALEX SC and Phesgo.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- ENHANZE:
- Halozyme's drug delivery technology that lets partners convert intravenous medicines into faster subcutaneous injections.
- Non-GAAP diluted EPS:
- Earnings per share adjusted by the company to exclude certain items, rather than calculated under standard accounting rules.
- Adjusted EBITDA:
- Earnings before interest, taxes, depreciation and amortization, excluding certain one-time items.
- Convertible notes:
- Debt that can be converted into company shares under set conditions.
FAQ
How much did Halozyme's revenue grow in the third quarter of 2026?
Total revenue rose 39% year over year to $493.0 million, and royalty revenue rose 44% to $341.0 million.
What did Halozyme change in its 2026 guidance?
The company raised its full year 2026 guidance, now expecting total revenue of $1.860 to $1.925 billion and royalty revenue of $1.235 to $1.255 billion.
Does the guidance include new investments?
Yes, the adjusted EBITDA and EPS guidance include approximately $60 million of new Hypercon and Aerocon investments.
Historical context for HALO
Across the 28 sessions after earlier HALO headlines, the stock closed higher 16 times and lower 12 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | HALO | SPY |
|---|---|---|---|
| Oct 22, 2026 | Halozyme to Report Third Quarter 2026 Financial and Operating Results | -0.2% | -1.2% |
| Oct 7, 2026 | Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Marketsand 1 other headline that session | +1.0% | -0.2% |
| Oct 1, 2026 | Halozyme Announces Appointment of Jim Daly to its Board of Directors | -3.1% | +0.2% |
| Sep 18, 2026 | Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 | +2.5% | -0.1% |
| Sep 17, 2026 | Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 | +1.1% | +1.1% |
| Sep 2, 2026 | Halozyme to Participate at Upcoming Investor Conferences | +1.8% | +0.4% |
Keep researching HALO
- HALO earnings historyPast Halozyme Therapeutics Inc. earnings releases, newest first.
- What is Earnings per share?A company's net income available to common shareholders divided by its weighted average shares outstanding, reported as basic and diluted figures.
- How to read an earnings reportAn earnings report is a company's quarterly results release, usually filed under 8-K Item 2.02. Learn how to read revenue, EPS, margins, guidance and the 10-Q.
- Earnings calendarWho reports this week, and the results as they come out.
- HALO financial statementsRevenue, profit, cash flow and balance sheet from Halozyme Therapeutics Inc.'s SEC filings.
- HALO insider tradesEvery buy and sale reported by Halozyme Therapeutics Inc. officers, directors and large holders.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Follow HALO and get a push notification the moment its next story breaks.